Project
Project #13292
Step by step one goes very far
Logged as guest
#13292 : The anti-IgE antibody Omalizumab induces adverse reactions through engagement of Fc gamma receptors
Topics : Organisms :
Group : Name of Applicant : Bianca Balbino Date of application : 03-06-2019 Unit : Antibodies in Therapy and Pathology Location : Metchnikoff - 4eme etage - room 4006A Phone : 9146@ Mail : bbalbino@pasteur.fr@ PI-Mail : pierre.bruhns@pasteur.fr
Project context and summary :
The therapeutic anti-IgE antibody Omalizumab is used for the treatment of severe asthma, and is known to trigger anaphylaxis in some patients. Since Omalizumab is a humanized IgG1, so we hypothesized that Omalizumab could trigger anaphylaxis through the alternative FcgR-mediated pathway. Indeed, we observed that Omalizumab can trigger anaphylaxis in genetically modified mice expressing human FcgRs. We further produced a mutant version of Omalizumab which can still block IgE but cannot bind FcgRs, and demonstrated that this mutant anti-IgE does not induce FcgR-mediated anaphylaxis.
Related team publications : Service Delivery
Project Manager : gael.millot@pasteur.frProject Type : ShortStatus : ClosedPublication : https://doi.org/10.1172/JCI129697Global Satisfaction for this application : Excellent (5/5)